After opening, CytoDyn Inc. (OTCMKTS:CYDY) has been moving in a narrow range. Will it continue to fall?
As of 12:43, CYDY is trading flat at $1.88. Volume 8.593 million shares, double the 30-day average volume. CYDY opened at $1.95 and has ranged between $1.79 and $2.18.
CYDY Will Publish Results Of Its CD12 Phase 3 Clinical Trial
- CytoDyn announced today that it will publish the results of its newly completed top-line report of its CD12 phase 3 clinical trial data for severe to critical patients to various agencies including India and the Philippines.
- The results were measured for 28 days. From day zero to seven patients receiving leronlimab experienced a mortality rate of 78% and patients receiving the second dose achieved a maximum benefit of 82% less mortality.
- A total of two doses were given to the patients in the CD12 trial.
|SHARES OUTSTANDING||612.88 M|
|SHARE FLOAT (%)||550.66 M (89.85%)|
|% HELD BY INSTITUTIONS||0.13|
Recent Stock Performance
|+/- EMA(20)||2.72 (-29.41%)|
|+/- SMA(50)||2.79 (-31.18%)|
|+/- SMA(200)||3.66 (-47.54%)|
|CCI20||-190.6631||Sell||Chaikin Money Flow||-0.2744||Sell|
|MACD||-0.3589||Sell||Money Flow Index||39.1803||Buy|
|STOCH (14,3)||6.4516||OverSold||STOCH RSI||0.0000||OverSold|